




BL = Baseline; EOW = Every other week; EW = Every week; PBO = Placebo; SC = Subcutaneous; W = Week
Subject dosing is every week with the final dose at Week 15.

FIG. 1

Proportion of Subjects Achieving HiSCR by Visit (NRI-MI) (ITT_1 Population)




FIG. 2

Proportion of Subjects Achieving NRS30 among Baseline NRS $\geq$ 3 by Visit (NRI-MI)
(ITT_1 Population)




FIG. 3

Proportion of Subjects Achieving HiSCR 75 by Visit (NRI-MI)
(ITT_1 Population)




FIG. 4

Proportion of Subjects Achieving HiSCR 90 by Visit (NRI-MI)
(ITT_1 Population)




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11